David Lebowitz Analyst PerformanceSenior Research Analyst at CitigroupDavid Lebowitz is a stock analyst at Citigroup in the medical sector, covering 14 publicly traded companies. Over the past year, David Lebowitz has issued 24 stock ratings, including buy, hold, and sell recommendations. While full access to David Lebowitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Lebowitz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings24 Last 0 YearsBuy Recommendations66.67% 16 Buy RatingsCompanies Covered14 Unique Companies Ratings Distribution24RatingsDistribution of strong buy, buy, hold, and sell ratings by David Lebowitz.RatingPercentageCount Strong Buy0.0%0 ratings Buy66.7%16 ratings Hold29.2%7 ratings Sell4.2%1 ratingsOut of 24 total stock ratings issued by David Lebowitz at Citigroup, the majority (66.7%) have been Buy recommendations, followed by 29.2% Hold and 4.2% Sell.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ14 companiesDavid Lebowitz, an analyst at Citigroup, currently covers 14 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies100.0%David Lebowitz of Citigroup specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE11 companies78.6%MED - DRUGS1 company7.1%MEDICAL INFO SYS1 company7.1%MED - GENERIC DRG1 company7.1% About David LebowitzDavid Lebowitz currently works at Citigroup Global Markets, Inc. (Broker), as Senior Research Analyst from 2021. Mr. Lebowitz also formerly worked at Piper Sandler & Co. (Broker), as Research Analyst from 2013 to 2014, Morgan Stanley & Co. LLC, as Equity Analyst from 2015 to 2021, Summit Technology, Inc., as Regulatory Specialist in 1999, SMH Capital, Inc. (Capital Markets), as Vice President & Senior Research Analyst from 2007 to 2008, Thomas Weisel Partners LLC, as Vice President & Senior Research Analyst from 2003 to 2006, Janney Montgomery Scott LLC, as Research Analyst from 2014 to 2015, and SG Cowen Securities Corp., as Equity Research Associate in 2002. Mr. Lebowitz received his graduate degree from The Trustees of Columbia University in The City of New York, undergraduate degree from Brandeis University, and Masters Business Admin degree from The Leonard N Stern School of Business.Follow on LinkedIn David Lebowitz's Ratings History at Citigroup Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIONSIonis Pharmaceuticals9/3/2025Boost Price Target$60.15$84.00Buy$0.0000.00% ROICYTKCytokinetics9/2/2025Boost Price Target$48.12$84.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals8/22/2025Boost Price Target$42.29$69.00Buy$0.0000.00% ROICLDXCelldex Therapeutics8/20/2025Lower Price Target$21.36$48.00Buy$0.0000.00% ROISDGRSchrodinger8/15/2025Downgrade$19.45$20.00Neutral$0.0000.00% ROIASNDAscendis Pharma A/S8/8/2025Reiterated Rating$191.49$290.00Buy$0.0000.00% ROICYTKCytokinetics8/8/2025Lower Price Target$34.11$77.00Buy$0.0000.00% ROIINCYIncyte7/30/2025Boost Price Target$78.05$103.00Buy$0.0000.00% ROIVKTXViking Therapeutics7/24/2025Boost Price Target$33.29$38.00Neutral$0.0000.00% ROICOGTCogent Biosciences7/18/2025Boost Price Target$12.46$22.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma7/11/2025Boost Price Target$46.34$67.00Buy$0.0000.00% ROIASNDAscendis Pharma A/S7/11/2025Boost Price Target$175.67$243.00Buy$0.0000.00% ROIBPMCBlueprint Medicines6/4/2025Upgrade$127.60$129.00Hold$0.0000.00% ROIEXELExelixis5/15/2025Boost Price Target$47.21$56.00Buy$0.0000.00% ROINTLAIntellia Therapeutics5/9/2025Lower Price Target$8.38$10.00Neutral$0.0000.00% ROINTLAIntellia Therapeutics2/28/2025Boost Price Target$9.88$14.00Neutral$0.0000.00% ROIBBIOBridgeBio Pharma2/21/2025Boost Price Target$36.88$49.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals2/20/2025Lower Price Target$32.57$64.00Buy$0.0000.00% ROIPTCTPTC Therapeutics2/12/2025Boost Price Target$48.63$45.00Sell$0.0000.00% ROIEXELExelixis2/12/2025Boost Price Target$33.18$45.00Buy$0.0000.00% ROIINCYIncyte2/11/2025Lower Price Target$68.30$88.00Buy$0.0000.00% ROIPLRXPliant Therapeutics2/10/2025Downgrade$7.79$4.00Neutral$0.0000.00% ROICYTKCytokinetics2/7/2025Initiated Coverage$46.17$86.00Buy$0.0000.00% ROIVKTXViking Therapeutics2/7/2025Initiated Coverage$31.46$38.00Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.